Contera Pharma announces first patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in a Phase 1b pharmacoscintigraphic study evaluating CP-012. This novel delayed-release, dual-pulse levodopa/carbidopa tablet is designed to address the distinct challenges of nocturnal immobility and early morning akinesia in Parkinson’s disease (PD) patients. These […]